Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIVITROL 380mg (naltrexone)
- Development stage
- Approved
- Lead developer
- Alkermes
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Vivitrol 380mg (naltrexone for extended-release injectable suspension) is a once-monthly, long-acting formulation of the opioid receptor antagonist naltrexone. Developed by Alkermes using its proprietary Medisorb® microsphere drug delivery technology, Vivitrol is administered as a deep intramuscular gluteal injection. It is FDA-approved for the treatment of alcohol dependence in patients who can abstain from alcohol in an outpatient setting, and for the prevention of relapse to opioid dependence following opioid detoxification. By binding competitively to opioid receptors (primarily mu-opioid receptors) in the brain, naltrexone blocks the euphoric and reinforcing effects of both exogenous opioids and endogenous endorphins, thereby reducing cravings and preventing relapse.
- Brand names
- VivitrolVivitrol 380mgVivitrol380mgVivitrol-380mg
- Other names
- Medisorb NaltrexoneVivitrexXL-NTXXR-NTXextended-release injectable naltrexonenaltrexone extended-releasenaltrexone for extended-release injectable suspension
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on VIVITROL 380mg (naltrexone).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIVITROL 380mg (naltrexone).